Drug Profile
GS 649443
Alternative Names: GS-649443Latest Information Update: 03 Oct 2023
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Class Antineoplastics
- Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 03 Oct 2023 Discontinued - Preclinical for Precursor cell lymphoblastic leukaemia-lymphoma in USA (PO) (Gilead Sciences pipeline, October 2023)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Precursor-cell-lymphoblastic-leukaemia-lymphoma in USA (PO)
- 03 Dec 2016 Preclinical trials in Acute lymphoblastic leukaemia in USA (PO)